Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:allows |
targeted DNA alteration
|
| gptkbp:basedOn |
bacterial immune system
|
| gptkbp:developedBy |
gptkb:Emmanuelle_Charpentier
gptkb:Jennifer_Doudna |
| gptkbp:hasCitations |
off-target effects
regulatory hurdles delivery mechanisms |
| gptkbp:hasProductLine |
germline editing
designer babies biodiversity impact |
| gptkbp:hasRelatedPatent |
gene therapy
pharmaceuticals synthetic biology reduce disease prevalence improve food security revolutionize medicine |
| https://www.w3.org/2000/01/rdf-schema#label |
CRISPR Technology
|
| gptkbp:isAttendedBy |
collaborative research
international partnerships technological innovations |
| gptkbp:isBasedOn |
Cas9 protein
CRISPR sequences |
| gptkbp:isDiscussedIn |
media outlets
conferences scientific journals |
| gptkbp:isInfluencedBy |
public policy
scientific ethics healthcare practices |
| gptkbp:isPartOf |
molecular biology
genomic research modern biotechnology |
| gptkbp:isPopularIn |
universities
research institutions biotech companies |
| gptkbp:isRegulatedBy |
government agencies
ethical committees |
| gptkbp:isStudiedIn |
clinical trials
laboratories |
| gptkbp:isSupportedBy |
grants
public funding private funding |
| gptkbp:isUsedFor |
treat genetic disorders
develop new therapies enhance crop resistance create genetically modified organisms other gene editing technologies |
| gptkbp:usedFor |
gene editing
genome modification |
| gptkbp:usedIn |
agriculture
medicine biomedical research |